[Prostatic urethral lift using Urolift® system for benign prostatic hyperplasia: 7years experience]

Area of Science:

• Urology
• Minimally Invasive Surgery
• Benign Prostatic Hyperplasia (BPH) Management

Background:

• Benign prostatic hyperplasia (BPH) is a common condition requiring treatment.
• The UroLift® system presents a minimally invasive alternative to traditional BPH surgery.
• Long-term outcomes of the UroLift® system in a clinical setting require evaluation.

Purpose of the Study:

• To report the 7-year experience with the UroLift® system at a single center.
• To assess the efficacy and safety of UroLift® implants for symptomatic BPH.
• To evaluate patient-reported outcomes, including urinary symptoms, quality of life, and sexual function.

Main Methods:

• A cohort of 40 patients with symptomatic BPH received UroLift® implants between 2012 and 2019.
• Efficacy was measured using the International Prostate Symptom Score (IPSS) and IPSS-Quality of Life (IPSS-QdV).
• Sexual function (IIEF5, MSHQ-EjD) and complication rates were assessed; survival analysis was performed using Kaplan-Meier.

Main Results:

• Significant improvements in IPSS (8 vs. 20) and IPSS-QdV (2 vs. 5) were observed at 3 months post-procedure (P<0.0001).
• No significant changes in erectile function (IIEF5) or ejaculatory function (MSHQ-EjD) were noted.
• A 5-year survival rate of 63% without additional treatment was achieved; 5% experienced temporary urinary retention.

Conclusions:

• UroLift® implants provide significant relief from lower urinary tract symptoms in BPH patients.
• The procedure demonstrates a favorable safety and tolerance profile, with minimal impact on sexual function.
• Over 60% of patients remained free from additional BPH treatments five years post-implantation.